Proteon Therapeutics Company Profile (NASDAQ:PRTO)

About Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics logoProteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $20.96 million
  • Outstanding Shares: 16,771,000
Average Prices:
  • 50 Day Moving Avg: $1.46
  • 200 Day Moving Avg: $3.16
  • 52 Week Range: $1.20 - $11.45
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.93
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.97 per share
  • Price / Book: 0.63
  • EBIDTA: ($28,230,000.00)
  • Return on Equity: -51.48%
  • Return on Assets: -47.65%
  • Current Ratio: 9.86%
  • Quick Ratio: 9.86%
  • Average Volume: 179,781 shs.
  • Beta: 1.72
  • Short Ratio: 2.06

Frequently Asked Questions for Proteon Therapeutics (NASDAQ:PRTO)

What is Proteon Therapeutics' stock symbol?

Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."

How were Proteon Therapeutics' earnings last quarter?

Proteon Therapeutics Inc (NASDAQ:PRTO) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.39) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.43) by $0.04. View Proteon Therapeutics' Earnings History.

Where is Proteon Therapeutics' stock going? Where will Proteon Therapeutics' stock price be in 2017?

8 analysts have issued 1-year price objectives for Proteon Therapeutics' shares. Their predictions range from $3.00 to $21.00. On average, they anticipate Proteon Therapeutics' share price to reach $9.17 in the next year. View Analyst Ratings for Proteon Therapeutics.

What are analysts saying about Proteon Therapeutics stock?

Here are some recent quotes from research analysts about Proteon Therapeutics stock:

  • 1. According to Zacks Investment Research, "Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. " (5/17/2017)
  • 2. Robert W. Baird analysts commented, "Focus of the call was on changes to the ongoing PATENCY-2 study of vonapanitase, following disappointing results from the first identically designed PATENCY-1 study announced late last year. Key changes, supported by the FDA, include a reordering of the primary endpoint (now a co-primary) and expanding the study (300 to 500 patients), with data now expected in 4Q18 (2Q18 previously). While we are encouraged by a potential path forward for vonapanitase, lack of meaningful updates near-term keeps us on the sidelines." (3/16/2017)
  • 3. Maxim Group analysts commented, "Proteon reported YE16 with a net loss of $28.5M and ended the year with $41M in cash on the balance sheet." (3/16/2017)

Who are some of Proteon Therapeutics' key competitors?

Who owns Proteon Therapeutics stock?

Proteon Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FLYNN JAMES E (7.30%), Pharmstandard International S.A. (7.02%), Perceptive Advisors LLC (2.01%), Deer VII & Co. Ltd. (1.90%) and Vanguard Group Inc. (1.43%). Company insiders that own Proteon Therapeutics stock include Daniel Philip Gottlieb, George Arthur Eldridge and Timothy P Noyes. View Institutional Ownership Trends for Proteon Therapeutics.

Who bought Proteon Therapeutics stock? Who is buying Proteon Therapeutics stock?

Proteon Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Proteon Therapeutics.

How do I buy Proteon Therapeutics stock?

Shares of Proteon Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Proteon Therapeutics stock cost?

One share of Proteon Therapeutics stock can currently be purchased for approximately $1.25.

Analyst Ratings

Consensus Ratings for Proteon Therapeutics (NASDAQ:PRTO) (?)
Ratings Breakdown: 7 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.13)
Consensus Price Target: $9.17 (633.33% upside)

Analysts' Ratings History for Proteon Therapeutics (NASDAQ:PRTO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/13/2017HC WainwrightSet Price TargetHold$3.00LowView Rating Details
5/4/2017Maxim GroupSet Price TargetBuy$6.00HighView Rating Details
3/16/2017Robert W. BairdReiterated RatingNeutral$3.00LowView Rating Details
1/17/2017Oppenheimer Holdings Inc.Reiterated RatingHoldN/AView Rating Details
12/14/2016Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
12/14/2016Raymond James Financial, Inc.Reiterated RatingStrong-Buy -> Market PerformN/AView Rating Details
12/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
12/14/2016Stifel NicolausDowngradeBuy -> Hold$19.00 -> $3.00N/AView Rating Details
(Data available from 5/28/2015 forward)


Earnings History for Proteon Therapeutics (NASDAQ:PRTO)
Earnings by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Earnings History by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.43)($0.39)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.46)($0.43)ViewN/AView Earnings Details
5/9/2016Q1($0.41)($0.40)ViewN/AView Earnings Details
3/14/2016($0.34)($0.39)ViewN/AView Earnings Details
11/12/2015Q315($0.33)($0.33)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.31)ViewN/AView Earnings Details
5/13/2015($0.24)($0.28)ViewN/AView Earnings Details
3/20/2015($0.26)($0.24)ViewN/AView Earnings Details
11/25/2014($0.31)($31.03)$2.95 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Proteon Therapeutics (NASDAQ:PRTO)
2017 EPS Consensus Estimate: ($1.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.44)($0.44)($0.44)
Q2 20171($0.44)($0.44)($0.44)
Q3 20171($0.44)($0.44)($0.44)
Q4 20171($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)


Dividend History for Proteon Therapeutics (NASDAQ:PRTO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Proteon Therapeutics (NASDAQ:PRTO)
Insider Ownership Percentage: 50.90%
Institutional Ownership Percentage: 49.28%
Insider Trades by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Institutional Ownership by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Insider Trades by Quarter for Proteon Therapeutics (NASDAQ:PRTO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/6/2016George Arthur EldridgeCFOBuy4,000$5.78$23,120.00View SEC Filing  
12/1/2015Timothy P. NoyesCEOSell5,000$14.97$74,850.00View SEC Filing  
11/2/2015Timothy P. NoyesCEOSell5,000$13.50$67,500.00View SEC Filing  
10/1/2015Timothy P. NoyesCEOSell5,000$13.33$66,650.00View SEC Filing  
9/8/2015Timothy P. NoyesCEOSell5,000$13.55$67,750.00View SEC Filing  
7/7/2015Daniel Philip GottliebVPSell1,965$16.86$33,129.90View SEC Filing  
10/27/2014James E FlynnInsiderBuy691,713$10.00$6,917,130.00View SEC Filing  
10/27/2014Skyline Venture Partners QualiMajor ShareholderSell56,038$10.00$560,380.00View SEC Filing  
10/27/2014Timothy HainesDirectorBuy950,000$10.00$9,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Proteon Therapeutics (NASDAQ:PRTO)
Latest Headlines for Proteon Therapeutics (NASDAQ:PRTO)
DateHeadline logoProteon Therapeutics Inc (PRTO) Given Average Rating of "Hold" by Analysts - May 26 at 9:04 PM logoProteon Therapeutics Inc (PRTO) Stock Rating Lowered by Zacks Investment Research - May 17 at 7:50 AM logoProteon Therapeutics Inc (PRTO) Announces Earnings Results, Beats Expectations By $0.04 EPS - May 11 at 10:52 PM logoProteon Therapeutics Announces First Quarter 2017 Financial Results - May 10 at 7:33 PM logoPre-Open Stock Movers 05/10: (PRTO) (NVDA) (INCR) Higher; (YELP) (VSI) (FOSL) Lower (more...) - May 10 at 11:29 AM logoProteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase - May 10 at 11:29 AM logoProteon Therapeutics reports 1Q loss - May 10 at 8:13 AM logoMaxim Group Analysts Give Proteon Therapeutics Inc (PRTO) a $6.00 Price Target - May 7 at 7:34 AM logoProteon Therapeutics (PRTO) Earning Somewhat Positive News Coverage, Report Shows - May 3 at 1:11 AM logoProteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial - May 2 at 5:09 PM logoProteon Therapeutics Inc (PRTO) Receives Consensus Rating of "Hold" from Analysts - May 1 at 10:42 PM logoProteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th - May 1 at 11:11 AM logo Brokerages Expect Proteon Therapeutics Inc (PRTO) to Announce -$0.45 EPS - May 1 at 11:05 AM logoProteon Therapeutics (PRTO) Receiving Somewhat Negative Media Coverage, Analysis Finds - April 28 at 3:08 PM logoProteon Therapeutics (PRTO) Given Media Sentiment Score of 0.12 - April 23 at 8:09 PM logoProteon Therapeutics (PRTO) Given News Sentiment Score of 0.06 - April 21 at 12:33 AM logoProteon Therapeutics (PRTO) Earning Somewhat Negative Press Coverage, AlphaOne Reports - April 15 at 2:13 PM logo-$0.45 EPS Expected for Proteon Therapeutics Inc (PRTO) This Quarter - April 8 at 12:24 AM logoProteon Therapeutics Inc (PRTO) Short Interest Update - April 7 at 5:31 PM logoProteon Therapeutics Inc (PRTO) Receives Average Recommendation of "Hold" from Brokerages - April 4 at 6:09 PM logoProteon Therapeutics Inc (PRTO) Stock Rating Upgraded by Zacks Investment Research - March 27 at 10:08 AM logoProteon Therapeutics Inc (PRTO) Upgraded to Buy by Zacks Investment Research - March 25 at 2:39 PM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible ... - Business Wire (press release) - March 24 at 8:16 AM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Proteon Therapeutics, Inc. - March 23 at 7:47 PM logoPROTEON THERAPEUTICS INC Financials - March 22 at 7:19 PM logoMaxim Group Reiterates Buy Rating for Proteon Therapeutics Inc (PRTO) - March 22 at 8:13 AM logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - March 22 at 7:30 AM logoProteon Therapeutics' (PRTO) Management Discuses Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial ... - Seeking Alpha - March 17 at 7:28 PM logoProteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd - March 17 at 7:28 PM logoProteon CEO: New trial could be a path to market - March 17 at 7:28 PM logoHC Wainwright Lowers Proteon Therapeutics Inc (PRTO) to Neutral - March 17 at 11:19 AM logoPROTEON THERAPEUTICS INC Files SEC form 10-K, Annual Report - March 16 at 8:07 PM logoPROTEON THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, - March 16 at 8:07 PM logoForm 8-K PROTEON THERAPEUTICS For: Mar 16 - - March 16 at 8:26 AM logoProteon Therapeutics Inc (PRTO) Set to Announce Quarterly Earnings on Monday - March 11 at 12:42 AM logoProteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology Meeting - February 14 at 5:21 AM logoProteon Therapeutics (PRTO) Announces Two Presentations at ASDIN Meeting - February 6 at 7:26 PM logoProteon Therapeutics Inc. (PRTN) Has Plunged To A New Low After Study Failed - December 14 at 8:09 PM logoFailure in late clinical trial pummels Proteon Therapeutics stock - December 14 at 8:09 PM logoProteon Slips to 52-Week Low on Kidney Disease Study Data - December 14 at 8:22 AM logo7:00 am Proteon Therapeutics announces that its first Phase 3 clinical trial with investigational vonapanitase did not meet its primary endpoint of improved primary unassisted patency compared to placebo (shares halted) - December 13 at 7:43 PM logoWaltham biotech's shares tank after kidney disease drug flunks trial - December 13 at 7:43 PM logoProteon Therapeutics downgraded by Robert W. Baird - December 13 at 7:43 PM logoProteon Therapeutics Craters on Missed Late-Stage Results - December 13 at 7:43 PM logoProteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD - December 13 at 8:41 AM logoProteon Therapeutics kidney drug fails key study - December 13 at 8:41 AM logoProteon Therapeutics' stock plummets after failed trial of kidney disease treatment - December 13 at 8:41 AM logo8:23 am Proteon Therapeutics reports Q3 results; beats by $0.04; provides a cash balance & milestone update - November 7 at 10:50 AM logoProteon Therapeutics Announces Overview of Phase 1 Clinical Program of Investigational Vonapanitase in Peripheral Artery Disease to be Presented at the 28th Transcatheter Cardiovascular Therapeutics (TCT) Conference - October 25 at 12:01 PM logoProteon Therapeutics Announces Second Quarter 2016 Financial Results - August 8 at 7:11 PM



Proteon Therapeutics (PRTO) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by Staff